Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Cash from Restructuring of $480000.0 in Q1 2026, up 111.13% quarter-over-quarter from -$4.3 million in Q4 2025.
Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Restructuring history runs 4 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- In Q1 2026, Cash from Restructuring changed N/A year-over-year to $480000.0; the TTM figure through Mar 2026 stood at $13.8 million (changed N/A YoY), while the FY2025 annual figure was $13.3 million, changed N/A from the prior year.
- Cash from Restructuring was $480000.0 for Q1 2026 at Prothena Corp Public, up from -$4.3 million in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $30.3 million in Q2 2025 to a low of -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | -4.31 Mn |
| Sep 30, 2025 | -12.72 Mn |
| Jun 30, 2025 | 30.33 Mn |
| Mar 31, 2019 | -461,000.00 |
| Dec 31, 2018 | -3.88 Mn |
| Sep 30, 2018 | -11.54 Mn |
| Jun 30, 2018 | 15.88 Mn |